Dr. Reddy's Laboratories Ltd ADR(RDY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 38.88 | EPS (ttm) | 0.36 | Insider Own | - | Shs Outstand | 833.1M | Perf Week | 7.28% |
| Market Cap | 11.79B | Forward P/E | 23.14 | EPS next Y | 34.11% | Insider Trans | - | Shs Float | - | Perf Month | 10.12% |
| Enterprise Value | 11.78B | PEG | 1.87 | EPS next Q | 0.13 | Inst Own | 14.23% | Short Float | - | Perf Quarter | 19.61% |
| Income | 0.30B | P/S | 3.31 | EPS this Y | -15.2% | Inst Trans | -3.03% | Short Ratio | 8.95 | Perf Half Y | 3.06% |
| Sales | 3.56B | P/B | 2.93 | EPS next 5Y | 12.38% | ROA | 5.02% | Short Interest | 26.14M | Perf YTD | 0.78% |
| Book/sh | 4.84 | P/C | 14.81 | EPS past 3/5Y | -4.82% 15.78% | ROE | 7.52% | 52W High | -9.7% ($15.67) | Perf Year | -3.08% |
| Cash/sh | 0.96 | P/FCF | 90.36 | Sales past 3/5Y | 7.5% 8.27% | ROIC | 7.31% | 52W Low | 24.56% ($11.36) | Perf 3Y | 8.76% |
| Dividend Est. | $0.08 (0.57%) | EV/EBITDA | 21.42 | EPS Y/Y TTM | -55.45% | Gross Margin | 45.82% | Volatility(W/M) | 2.49% 1.92% | Perf 5Y | 15.85% |
| Dividend TTM | 0.08 | EV/Sales | 3.31 | Sales Y/Y TTM | -10.52% | Oper. Margin | 8.95% | ATR (14) | 0.31 | Perf 10Y | 42.53% |
| Dividend Ex-Date | 2026/7/24 | Quick Ratio | 1.4 | EPS Q/Q | -41.16% | Profit Margin | 8.52% | RSI (14) | 78.46 | Recom | 2.33 |
| Dividend Gr. 3/5Y | -9.14% - | Current Ratio | 1.93 | Sales Q/Q | -10.05% | SMA20 | 9.61% ($12.91) | Beta | 0.33 | Target Price | $14.14 |
| Payout | 11.04% | Debt/Eq | 0.19 | Earnings | 2026/10/23 | SMA50 | 13.57% ($12.46) | Rel Volume | 1.53 | Prev Close | $13.75 |
| Employees | 27527 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 20.45% 1.78% | SMA200 | 7.15% ($13.21) | Avg Volume(3M) | 2.92M | Price | $14.15 |
| IPO | 2001/4/11 | Option/Short | Yes/Yes | Trades | 13821 | Volume | 4,468,881 | Change | 2.91% |
An Indian pharmaceutical company that develops and manufactures generic drugs, active pharmaceutical ingredients (APIs), and biosimilars, supplying them to the United States, India, and emerging markets. It is a global generic and specialty pharmaceutical company listed on the US stock exchange as an ADR.
Over the past 1 year, roughly in the middle
10% below its 1-year high.
Traded more than usual. That is 153% of its average volume.
RDY earns at a steady pace
Of every $100 in sales, $8.95 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -15.2% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $3,888. Peers typically go for $2,097.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 5 years ago, your return today would be +15.8%. The S&P 500 did +69% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 0.57% annually in dividends.
Tap to view numbers
Ownership is about average
Institutions hold 14.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #8 of 83 in the industry
Based on market cap of $12B.
NBIX#7 Neurocrine Biosciences Inc $15B PER 21.3 RDY#8 Dr. Reddy's Laboratories Ltd ADR $12B PER 38.9 
ELAN#9 Elanco Animal Health Inc $11B PER - 
ALKS#10 Alkermes plc $8B PER 117.5 
KNSA#11 Kiniksa Pharmaceuticals International Plc $7B PER 72.6 
FAQ
What kind of company is RDY?
RDY belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of RDY?
The market cap of RDY is approximately $11.8B, ranking 829 within its sector.
Does RDY pay dividends?
RDY has a dividend yield of approximately 0.57%, with an annual dividend of $0.08.
What is the P/E ratio of RDY?
RDY has a P/E ratio of approximately 38.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for RDY?
RDY has recorded a 52-week high of $15.67 and a low of $11.36.
